Natco Pharma

₹1362.4 -10 | 0.7%

WEBSITE BSE:524816 NSE : NATCO PHARM 26 Dec, 16:01

Market Cap ₹24401 Cr.

Stock P/E 17.6

P/B 3.6

Current Price ₹1362.4

Book Value ₹ 382

Face Value 2

52W High ₹1638.4

Dividend Yield 0.7%

52W Low ₹ 792.4

Edit Ratio

Natco Pharma Research see more...

Overview Inc. Year: 1981Industry: Pharmaceuticals & Drugs

Natco Pharma Ltd is a pharmaceutical company. The Company is engaged in developing, production and advertising finished dosage formulations (FDF) and active pharmaceutical elements (APIs). The Company's segments include energetic prescription drugs factor, finished dosage formulations, job works, pharmacy and others. The Company's product categories consist of Domestic Formulations, International Formulations, API's and Blockbusters. The Company's merchandise include Thioplan, Anastronat, Capnat, Fulvenat, Kabanat, Natdox-LP, Alphalan, Bandrone, Bendit, Clokeran, Lenalid, Rapact, Temonat, X-Trant, Glatimer, Hepcinat, Lansoprazole, Letrozole, Granisetron, Rizatriptan IR, Imatinib, Salmeterol Xinafoate, Sertraline Form I, Natdac, Natzold, Tigi, Alprazolam, Chloroquine Phosphate, Ibandronate Sodium Monohydrate, Pantoprazole Sodium Sesquihydrate, Ondansetron Hydrochloride (Injectable Grade), Daclatasvir and Glatiramer Acetate. The Company manufactures over 20 merchandise underneath contract.

Natco Pharma Share Price

New

Volume

Price

Price: NSE50 DMA200 DMAVolume

Quarterly Price

Quarterly Monthly

Show Value Show %

Peer Comparison

Natco Pharma Quarterly Results

#(Fig in Cr.)
Net Sales
Other Income
Total Income
Total Expenditure
Operating Profit
Interest
Depreciation
Exceptional Income / Expenses
Profit Before Tax
Provision for Tax
Profit After Tax
Adjustments
Profit After Adjustments
Adjusted Earnings Per Share

Natco Pharma Profit & Loss

#(Fig in Cr.)	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Net Sales	622	716	1021	1958	2091	1986	1790	1654	1768	2351	3569
Other Income	16	14	13	13	39	130	124	104	95	109	105
Total Income	638	729	1034	1971	2131	2116	1914	1757	1862	2460	3674
Total Expenditure	436	487	741	1266	1163	1170	1212	1238	1555	1530	1932
Operating Profit	202	242	294	705	968	946	702	519	308	930	1742
Interest	34	30	22	18	15	19	21	11	13	9	15
Depreciation	27	42	50	54	66	80	98	115	138	151	172
Exceptional Income / Expenses	0	-15	0	0	0	0	0	0	0	0	0
Profit Before Tax	141	154	222	634	888	847	583	392	156	771	1555
Provision for Tax	31	1	45	139	189	180	109	83	17	134	249
Profit After Tax	110	153	177	495	698	667	475	310	139	637	1307
Adjustments	0	0	0	0	0	0	0	0	0	0	0
Profit After Adjustments	110	153	177	495	698	667	475	310	139	637	1307
Adjusted Earnings Per Share	6.7	9.2	10.1	28.4	37.8	36.6	26.1	17	7.6	34.9	73

Growth Rates

#	1 Year	3 Year	5 Year	10 Year
Sales CAGR	52%	29%	12%	19%
Operating Profit CAGR	87%	50%	13%	24%
PAT CAGR	105%	62%	14%	28%

#	1 Year	3 Year	5 Year	10 Year
Share Price CAGR	69%	15%	19%	17%
ROE Average	25%	14%	13%	18%
ROCE Average	29%	16%	15%	21%

Natco Pharma Balance Sheet

#(Fig in Cr.)	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Shareholder's Funds	733	879	1336	1700	3125	3563	3870	4091	4192	4702	5592
Minority's Interest	0	0	0	0	0	0	0	0	0	0	0
Borrowings	95	96	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	54	21	28	38	47	83	118	143	135	117	69
Total Current Liabilities	295	398	479	610	564	710	660	519	651	569	886
Total Liabilities	1176	1395	1843	2347	3736	4356	4647	4753	4978	5388	6547
Fixed Assets	529	573	706	829	1015	1215	1575	2006	2174	2234	2287
Other Non-Current Assets	310	378	346	483	667	874	832	578	636	659	850
Total Current Assets	337	444	791	1035	2054	2267	2240	2169	2168	2495	3410
Total Assets	1176	1395	1843	2347	3736	4356	4647	4753	4978	5388	6547

Natco Pharma Cash Flow

#(Fig in Cr.)	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Opening Cash & Cash Equivalents	7	7	-170	19	13	10	12	8	5	6	7
Cash Flow from Operating Activities	172	125	190	330	476	699	423	184	58	784	1196
Cash Flow from Investing Activities	-131	-148	-249	-291	-1131	-645	-165	-3	-93	-437	-961
Cash Flow from Financing Activities	-41	23	151	-46	652	-52	-261	-183	36	-347	-237
Net Cash Inflow / Outflow	0	-1	92	-6	-3	1	-4	-3	1	1	-1
Closing Cash & Cash Equivalent	7	6	-77	13	10	12	8	5	6	7	6

Natco Pharma Ratios

#	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Earnings Per Share (Rs)	6.66	9.2	10.14	28.36	37.84	36.55	26.07	16.96	7.62	34.91	72.99
CEPS(Rs)	8.28	11.76	13.03	31.43	41.39	40.94	31.46	23.27	15.21	43.18	82.6
DPS(Rs)	1	1	1.25	6.75	8.25	6.25	6.75	5.25	4.5	5.5	9.5
Book NAV/Share(Rs)	44.32	52.9	76.24	96.52	168.09	193.55	211.31	223.21	229.51	257.64	312.42
Core EBITDA Margin(%)	29.7	31.44	26.5	34.55	44.03	37.52	30.61	24.64	11.56	34.23	43.56
EBIT Margin(%)	27.94	25.38	22.98	32.53	42.79	39.8	31.97	23.94	9.18	32.5	41.77
Pre Tax Margin(%)	22.52	21.24	20.91	31.66	42.1	38.94	30.88	23.27	8.46	32.14	41.39
PAT Margin (%)	17.54	21.04	16.66	24.71	33.11	30.65	25.13	18.36	7.55	26.57	34.77
Cash Profit Margin (%)	21.81	26.88	21.4	27.38	36.22	34.33	30.32	25.2	15.06	32.87	39.34
ROA(%)	9.87	11.9	10.9	23.62	22.95	16.49	10.54	6.59	2.86	12.29	21.9
ROE(%)	17.35	18.97	16	32.87	29.18	20.11	12.86	7.82	3.37	14.33	25.38
ROCE(%)	19.04	17.1	18.48	38.71	34.58	23.91	14.85	9.46	3.79	16.51	29.02
Receivable days	70.4	76.52	76.63	66.04	93.04	92.04	99.38	101.41	96.61	104.18	90.8
Inventory Days	84.34	90.45	94.81	62.77	66.02	78.34	99.81	140.07	145.29	100	58.9
Payable days	236.77	229.35	274.45	166.16	233.37	256.97	215.17	144.4	102.03	121.62	126.93
PER(x)	23.92	45.86	40.62	29.87	19.93	15.64	19.41	48.66	99.36	16.15	13.04
Price/Book(x)	3.6	7.98	5.4	8.78	4.49	2.95	2.4	3.7	3.3	2.19	3.05
Dividend Yield(%)	0.63	0.24	0.3	0.8	1.09	1.09	1.33	0.64	0.59	0.98	1
EV/Net Sales(x)	4.6	10.22	7.09	7.65	6.65	5.31	5.29	9.1	7.98	4.27	4.63
EV/Core EBITDA(x)	14.16	30.21	24.66	21.24	14.38	11.15	13.49	29.02	45.87	10.79	9.49
Net Sales Growth(%)	11.56	14.98	42.74	91.7	6.81	-5.02	-9.87	-7.64	6.91	32.99	51.8
EBIT Growth(%)	27.69	5.15	31.89	167.71	38.47	-4	-30.3	-33.16	-58.07	360.58	101.44
PAT Growth(%)	41.01	38.78	15.42	180.34	41.11	-4.45	-28.87	-34.77	-55.06	358.02	105.09
EPS Growth(%)	33.76	38.1	10.23	179.54	33.46	-3.41	-28.68	-34.95	-55.06	358.02	109.1
Debt/Equity(x)	0.32	0.35	0.08	0.13	0.06	0.11	0.08	0.06	0.09	0.03	0.06
Current Ratio(x)	1.14	1.12	1.65	1.7	3.64	3.19	3.4	4.18	3.33	4.38	3.85
Quick Ratio(x)	0.6	0.63	0.92	1.15	2.89	2.48	2.65	2.79	2.32	3.36	3.23
Interest Cover(x)	5.15	6.12	11.11	37.23	61.38	46.07	29.31	35.71	12.72	90.62	108.26
Total Debt/Mcap(x)	0.09	0.04	0.02	0.01	0.01	0.04	0.03	0.02	0.03	0.02	0.02

Natco Pharma Shareholding Pattern

#	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024
Promoter	48.8	48.8	48.82	48.84	49.76	49.71	49.71	49.71	49.71	49.62
FII	11.65	11.67	11.72	11.91	11.02	12.82	13.72	16.14	17.45	17.51
DII	15.29	14.3	14.93	15.37	15.15	14.01	11.25	9.7	7.86	6.75
Public	24.25	25.23	24.53	23.87	24.07	23.46	25.32	24.46	24.97	26.12
Others	0	0	0	0	0	0	0	0	0	0
Total	100	100	100	100	100	100	100	100	100	100

#	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024
Promoter	8.91	8.91	8.91	8.91	8.91	8.9	8.9	8.9	8.9	8.89
FII	2.13	2.13	2.14	2.17	1.97	2.3	2.46	2.89	3.13	3.14
DII	2.79	2.61	2.73	2.81	2.71	2.51	2.01	1.74	1.41	1.21
Public	4.43	4.61	4.48	4.36	4.31	4.2	4.54	4.38	4.47	4.68
Others	0	0	0	0	0	0	0	0	0	0
Total	18.26	18.26	18.26	18.25	17.91	17.91	17.91	17.91	17.91	17.91

Pros

Company is almost debt free.

Cons

Promoter holding is low: 49.62%.
Company has a low return on equity of 14% over the last 3 years.
Debtor days have increased from 121.62 to 126.93days.
Stock is trading at 3.6 times its book value.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Natco Pharma News

IPO

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Natco Pharma

Add Watchlist

Natco Pharma Research see more...

Overview Inc. Year: 1981Industry: Pharmaceuticals & Drugs

Natco Pharma Share Price

Alert Data

Quarterly Price

Peer Comparison

Natco Pharma Quarterly Results

Natco Pharma Profit & Loss

Growth Rates

Natco Pharma Balance Sheet

Natco Pharma Cash Flow

Natco Pharma Ratios

Natco Pharma Shareholding Pattern

Natco Pharma News

IPO

Stocx: India's #1 Marketplace to Find Your Winning Stock

Please Login!

Error!